BR112022023892A2 - Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos - Google Patents
Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usosInfo
- Publication number
- BR112022023892A2 BR112022023892A2 BR112022023892A BR112022023892A BR112022023892A2 BR 112022023892 A2 BR112022023892 A2 BR 112022023892A2 BR 112022023892 A BR112022023892 A BR 112022023892A BR 112022023892 A BR112022023892 A BR 112022023892A BR 112022023892 A2 BR112022023892 A2 BR 112022023892A2
- Authority
- BR
- Brazil
- Prior art keywords
- vsig4
- compositions
- methods
- myeloid cell
- cell phenotypes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
COMPOSIÇÕES ANTI-VSIG4 E MÉTODOS PARA MODULAR FENÓTIPOS INFLAMATÓRIOS DE CÉLULAS MI- ELOIDES E SEUS USOS. A presente invenção refere-se, em parte, na descoberta de composição anti-VSIG4 (por exemplo, anticorpos monoclonais e fragmentos de ligação ao antígeno dos mesmos), que regulam fenótipos inflamatórios de células mieloides, tais como células mieloides supressoras, monócitos, macrófagos, neutrófilos e/ou células dendríticas, incluindo polarização, ativação e/ou função e métodos de usar essas composições anti-VSIG4 para propósitos terapêuticos, diagnósticos, prognósticos e de triagem.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063032337P | 2020-05-29 | 2020-05-29 | |
PCT/US2021/034784 WO2021243169A1 (en) | 2020-05-29 | 2021-05-28 | Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022023892A2 true BR112022023892A2 (pt) | 2022-12-27 |
Family
ID=78722851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022023892A BR112022023892A2 (pt) | 2020-05-29 | 2021-05-28 | Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230348603A1 (pt) |
EP (1) | EP4157886A1 (pt) |
JP (1) | JP2023527410A (pt) |
KR (1) | KR20230017778A (pt) |
CN (1) | CN115996953A (pt) |
AU (1) | AU2021281356A1 (pt) |
BR (1) | BR112022023892A2 (pt) |
CA (1) | CA3182814A1 (pt) |
IL (1) | IL298545A (pt) |
TW (1) | TW202210523A (pt) |
WO (1) | WO2021243169A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023133338A2 (en) * | 2022-01-10 | 2023-07-13 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Molecules that bind to neutrophil elastase polypeptides |
KR20240058017A (ko) * | 2022-10-21 | 2024-05-03 | 주식회사 유틸렉스 | 항-vsig4 항체를 포함하는 항암용 조성물 |
CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062904A2 (en) * | 2008-11-25 | 2010-06-03 | Biogen Idec Ma Inc. | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
US9090679B2 (en) * | 2009-04-17 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
-
2021
- 2021-05-28 CN CN202180039150.1A patent/CN115996953A/zh active Pending
- 2021-05-28 US US17/999,503 patent/US20230348603A1/en active Pending
- 2021-05-28 IL IL298545A patent/IL298545A/en unknown
- 2021-05-28 KR KR1020227041080A patent/KR20230017778A/ko unknown
- 2021-05-28 CA CA3182814A patent/CA3182814A1/en active Pending
- 2021-05-28 BR BR112022023892A patent/BR112022023892A2/pt unknown
- 2021-05-28 AU AU2021281356A patent/AU2021281356A1/en active Pending
- 2021-05-28 JP JP2022573201A patent/JP2023527410A/ja active Pending
- 2021-05-28 WO PCT/US2021/034784 patent/WO2021243169A1/en unknown
- 2021-05-28 EP EP21814040.8A patent/EP4157886A1/en active Pending
- 2021-05-28 TW TW110119507A patent/TW202210523A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230017778A (ko) | 2023-02-06 |
EP4157886A1 (en) | 2023-04-05 |
JP2023527410A (ja) | 2023-06-28 |
CA3182814A1 (en) | 2021-12-02 |
CN115996953A (zh) | 2023-04-21 |
TW202210523A (zh) | 2022-03-16 |
US20230348603A1 (en) | 2023-11-02 |
IL298545A (en) | 2023-01-01 |
WO2021243169A1 (en) | 2021-12-02 |
AU2021281356A1 (en) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022023892A2 (pt) | Composições anti-vsig4 e métodos para modular fenótipos inflamatórios de células mieloides e seus usos | |
BR112021024314A2 (pt) | Composições e métodos anti-siglec-9 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
Zhai et al. | Attenuation of rheumatoid arthritis through the inhibition of tumor necrosis factor–induced caspase 3/gasdermin E–mediated pyroptosis | |
Li et al. | Hippo signaling controls NLR family pyrin domain containing 3 activation and governs immunoregulation of mesenchymal stem cells in mouse liver injury | |
Leung-Pineda et al. | Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit | |
Eppensteiner et al. | Damage-and pathogen-associated molecular patterns play differential roles in late mortality after critical illness | |
Lin et al. | Glycosylation‐dependent interaction between CD69 and S100A8/S100A9 complex is required for regulatory T‐cell differentiation | |
Tibaldi et al. | Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells | |
Goncalves et al. | Role of DC-SIGN in Lassa virus entry into human dendritic cells | |
Shi et al. | Antimicrobial peptaibols, novel suppressors of tumor cells, targeted calcium-mediated apoptosis and autophagy in human hepatocellular carcinoma cells | |
BR112021024242A2 (pt) | Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
Beaufort et al. | Disruption of the endothelial barrier by proteases from the bacterial pathogen Pseudomonas aeruginosa: implication of matrilysis and receptor cleavage | |
Nam et al. | Changes of the structural and biomechanical properties of the bovine pericardium after the removal of α-gal epitopes by decellularization and α-galactosidase treatment | |
BR112021026181A2 (pt) | Composições anti-cd53 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
BR112021026411A2 (pt) | Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos | |
Cho et al. | Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death | |
Xu et al. | Multiple pathways were involved in tubeimoside-1-induced cytotoxicity of HeLa cells | |
Chen et al. | Protein disulfide isomerase enhances tissue factor-dependent thrombin generation | |
Yu et al. | Identification of human plasma cells with a lamprey monoclonal antibody | |
Towhid et al. | Stimulation of platelet apoptosis by peptidoglycan from Staphylococcus aureus 113 | |
Taniuchi et al. | BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1 | |
Nicholas et al. | Dysfunctional mitochondria contain endogenous high-affinity human Toll-like receptor 4 (TLR4) ligands and induce TLR4-mediated inflammatory reactions | |
Martyanov et al. | Effects of bacterial lipopolysaccharides on platelet function: Inhibition of weak platelet activation | |
Jakoš et al. | Cysteine cathepsins L and X differentially modulate interactions between myeloid-derived suppressor cells and tumor cells | |
Shojaee et al. | Myosin translocation in retinal pericytes during free‐radical induced apoptosis |